Role of convalescent plasma therapy in new Coronavirus disease (nCOVID-19): A review

Abstract

Hitherto, there is no proper line of treatment for the new Coronavirus (nCOVID19). The development of unique antiviral drugs has taken precedence. Therapeutic neutralising antibodies (NABs) will be a significantly beneficial agent against nCOVID-19. Here the host immune responses to new Coronavirus discussed in this review provide strategy and further treatment and understanding of clinical interventions against nCOVID-19. Plasma therapy uses the antibodies found in the blood of people recovering (or convalesced) from an infection to treat infected patients. When an infection occurs, the body begins producing proteins specially made to kill the germ, called antibodies. Those antibodies coat specifically plasma in the blood of survivors, the yellow transparent liquid blood portion for months or even years. Recent research assesses plasma use from Convalescent patients of infected with nCOVID-19 as a possible preventive treatment. But it is not yet recommended as a line of treatment, and it is used as a clinical trial in the new Coronavirus in Indian population.